Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ASCO relevance

<< Previous

Bullboard Posts

Next >>

Comment by Geneman2004on Apr 29, 2023 7:34pm

160 Views

Post# 35421204

RE:RE:RE:RE:ASCO relevance

great to connect again. maybe there will be a collection of like-minded investors that emerge. There are lots of science topics and even more investing topics. The company has a whole new cohort of investors now and we will see what the tenor of discussion is. If it is crappy, there are lots of ways for a small number of motivated people to connect. We can just add our 2c and see how it goes.

cheers, Geneman

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta